AEON Biopharma announced it has raised additional capital after underwriters partially exercised their over-allotment option related to the company's public offering completed on July 15, 2026. The exercise resulted in the issuance and sale of additional shares of common stock.
Key Details
- Proceeds: The company received additional gross proceeds of approximately $1.5 million, resulting in net proceeds of about $1.4 million after underwriting discounts and commissions.
- Shares Issued: A total of 4,696,102 shares of Class A common stock were sold to the underwriters.
- Transaction Date: The sale of the over-allotment shares occurred on July 23, 2026.